







Extended Data Fig. 5e. Immunoblot of HEL cells treated with increasing doses of BCI or the MEK inhibitor trametinib. Cells were treated at their indicated drug dose for 24 hours.



Extended Data Fig. 5g. Immunoblot profiling of different signaling pathways altered by BCI and trametinib. HEL cells were treated with 1 μM or 1 μM trametinib for 24 hours.



Extended Data Fig. 5i. Immunoblot of HEL and UKE-1 cells treated with 1 μM BCI for 24 hours.



Extended Data Fig. 5j. Immunoblot of HEL cells ectopically expressing *DUSP6* or *GFP* control vector.